Physician profile
David E Biats
NPI 1609889427
$2,351.61
in general payments reported to CMS, 2019-2025
22 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2021: $281 · 2022: $13.41 · 2023: $601 · 2024: $1,064 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $328.90 | 2023-2025 | Veozah |
| Intuitive Surgical, INC. | $317.88 | 2021-2023 | |
| Sage Therapeutics, LLC | $255.99 | 2023-2025 | Zurzuvae |
| Biotissue Holdings INC. | $246.61 | 2024 | |
| Exact Sciences Corporation | $178.88 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $154.11 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $146.86 | 2023-2025 | Slynd |
| Organon LLC | $118.71 | 2023-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $86.53 | 2023-2024 | |
| Horizon Therapeutics Plc | $85.72 | 2023 | Tepezza |
| Hologic Sales and Service, LLC | $79.27 | 2023-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Amarin Pharma, INC. | $65.62 | 2019 | |
| Conmed Corporation | $64.61 | 2021 | |
| Pfizer INC. | $41.88 | 2024 | |
| Abbvie INC. | $41.81 | 2022-2023 | Lo Loestrin Fe, Orilissa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.94 | 2019 | |
| Agile Therapeutics, INC. | $24.86 | 2024 | Twirla |
| Amgen INC. | $22.18 | 2025 | Evenity |
| Minerva Surgical, INC | $20.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.44 | 2025 | Xifaxan |
| Therapeuticsmd, INC. | $13.39 | 2019 | |
| Millicent US INC | $8.34 | 2024 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Biats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.